Company Overview: Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences.
Clinical Trial Details: The Phase III trial, FLAMINGO-01, evaluates the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients, with plans to include up to 150 global clinical sites.
Research Coverage Initiation: Noble Capital Markets has begun company-sponsored equity research coverage on Greenwich LifeSciences, providing insights into their ongoing clinical efforts.
Breast Cancer Statistics: Approximately one in eight U.S. women will develop invasive breast cancer, highlighting the significance of HER2 positivity in treatment strategies, as it is present in 75% of breast cancers.
GLSI
$10.4+Infinity%1D
Analyst Views on GLSI
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.310
Low
45.00
Averages
45.00
High
45.00
Current: 10.310
Low
45.00
Averages
45.00
High
45.00
Noble Capital
Outperform
initiated
$45
2025-08-20
Reason
Noble Capital
Price Target
$45
2025-08-20
initiated
Outperform
Reason
Noble Capital initiated coverage of Greenwich LifeSciences with an Outperform rating and $45 price target. Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees "large market potential" for GLSI-100.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$38 → $39
2025-04-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$38 → $39
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$38
2025-02-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$38
2025-02-11
Reiterates
Strong Buy
Reason
About GLSI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
